A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

Cisplatin, Vinorelbine and radiotherapy

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CISPLATIN - VINORELBINE (RADIOTHERAPY) Regimen NSCLC – Cisplatin - Vinorelbine (Radiotherapy) Indication First line therapy of
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/CisplatinVinorelbineandradiotherapyver12.pdf

Cisplatin and Vinorelbine (intravenous-adjuvant)

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CISPLATIN-VINORELBINE (Intravenous - Adjuvant) Regimen NSCLC – Cisplatin-Vinorelbine (Intravenous-Adjuvant) Indication Adjuvant therapy
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/CisplatinandVinorelbineintravenous-adjuvantver12.pdf

Cisplatin and Vinorelbine (intravenous)

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CISPLATIN-VINORELBINE (Intravenous) Regimen NSCLC – Cisplatin-Vinorelbine IV Indication First line therapy of
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/CisplatinandVinorelbineintravenousver12.pdf

Cisplatin and Gemcitabine

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CISPLATIN-GEMCITABINE Regimen NSCLC – Cisplatin-Gemcitabine Indication Non-small cell lung cancer (in
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/CisplatinandGemcitabinever12.pdf

Ipilimumab(1mg/kg)-Nivolumab(3mg/kg)

Description
Chemotherapy Protocol RENAL CANCER IPILIMUMAB (1mg/kg)-NIVOLUMAB(3mg/kg) Regimen • Renal – Ipilimumab (1mg/kg)-Nivolumab (3mg/kg) Indication • Ipilimumab in
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Ipilimumab1mgkg-Nivolumab3mgkg.pdf

Bexarotene

Description
Chemotherapy Protocol Cutaneous T-cell Lymphoma BEXAROTENE Regimen • Cutaneous T-cell Lymphoma - Bexarotene Indication • Bexarotene is indicated for the treatment of
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Bexarotene.pdf

IRD(40)-Dexamethasone_40_Ixazomib-Lenalidomide

Description
Chemotherapy Protocol Myeloma IRD (40) - Dexamethasone (40)-Ixazomib-Lenalidomide Regimen • Myeloma – IRD (40) - Dexamethasone (40)-Ixazomib-Lenalidomide Indication • Ixazomib and lenalidomide
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/IRD40-Dexamethasone-40-Ixazomib-Lenalidomide.pdf

IRD(20)-Dexamethasone_20_Ixazomib-Lenalidomide

Description
Chemotherapy Protocol Myeloma IRD (20) - Dexamethasone (20)-Ixazomib-Lenalidomide Regimen • Myeloma – IRD (20) - Dexamethasone (20)-Ixazomib-Lenalidomide Indication • Ixazomib and lenalidomide
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/IRD20-Dexamethasone-20-Ixazomib-Lenalidomide.pdf

Dexamethasone(40)-Pomalidomide

Description
Regimen Chemotherapy Protocol Myeloma Dexamethasone (40)-Pomalidomide • Myeloma – Dexamethasone (40)-Pomalidomide Indication • Pomalidomide, in combination with dexamethasone, is recommended as an
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Dexamethasone-40-Pomalidomide.pdf

Dexamethasone(20)-Pomalidomide

Description
Chemotherapy Protocol Myeloma Dexamethasone (20)-Pomalidomide Regimen • Myeloma – Dexamethasone (20)-Pomalidomide Indication • Pomalidomide, in combination with low‑dose dexamethasone, is recommended
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Dexamethasone-20-Pomalidomide.pdf
171 to 180 of 1000
Previous … 16 17 18 19 20 … Next